Abstract: The invention provides a human Vps35/Mem3-related protein (hvmrp) and polynucleotides which identify and encode hvmrp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of hvmrp.

Abstract: An isolated and purified non-denatured outer membrane protein CD which is that of or corresponds to that isolatable from a Branhamella strain, particularly B. catarrhalis, is isolated from a bacterial strain by fractionating a cell lysate formed by disrupting a cell mass of the bacterial strain by centrifugation to provide a pellet and a discard supernatant containing a large proportion of soluble bacterial proteins. The pellet is selectively extracted to remove the remaining soluble proteins, the membrane proteins other than CD and other contaminants such as lipopolysaccharide and phospholipids. The remaining CD-containing pellet is dispersed and solubilized and then fractionated by centrifugation to remove the remaining cell debris.

Abstract: The present invention relates to a method of systemically administering a vaccine comprising live attenuated bacteria of the species Streptococcus equi in order to protect against Streptococcus equi infection.

Abstract: The present invention relates to a method for the enhancement of fluorescence wherein a fluorophor is connected to a textured material. The method can be used in any forensic or medical diagnostic assay, particularly where the absence or presence of a molecule having a concentration of less than about 1 .mu.g/ml is desirably determined.

Abstract: The invention concerns a hybrid plasmid for the expression of unfused 38 kDa antigen of M. tuberculosis in E. coli, E. coli with the plasmid, an 38 kDa antigen and a protein of about 33 kDa useful for diagnoses.

Abstract: Hybrid polypeptides are provided formed with encapsulating regions from genes that encode for anabolic proteins. More particularly, the present invention relates to recombinant nucleic acid molecules that code for genes which encapsulate an attached protein within a matrix; preferably, these genes encapsulate a desired ("payload") polypeptide within starch, and more specifically within the starch granule matrix. Expression vectors comprising these recombinant nucleic acid molecules, and hosts therefor, and more specifically the starch-bearing portions of such hosts, transformed with such vectors, are also provided. Preferably, grain containing a foreign protein encapsulated within the starch is provided, useful to produce mammalian, fish and avian food. The invention also encompasses methods of producing purified protein from starch and particularly from starch granules, and industrial uses of such protein.

Abstract: Disclosed are methods for the sterilization of a male mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the vas deferens of the male mammal.

Abstract: Live vaccines and methods for preparing the vaccines useful in protecting a host from infection by a pathogenic microorganism are provided. Vaccines are prepared from live Lactobacillus cells which have been transformed using DNA technology to express heterologous antigens of pathogenic microorganisms or other suitable biological material. Genes encoding antigenic determinants pathogenic in the mammalian gastrointestinal tract are inserted into expression cassettes and fused with genes encoding an aggregation factor and/or a mucin binding factor. The inserted genes are shown to transform L. reuteri cells. The aggregation enhancing and mucin binding genes have been isolated and sequenced. The vaccine can be ingested orally in a pharmaceutical carrier or in milk products.

Abstract: The present invention relates to parasitic helminth PLA2 proteins; to parasitic helminth PLA2 nucleic acid molecules, including those that encode such proteins; to antibodies raised against such proteins; and to compounds that inhibit parasitic helminth phospholipase A.sub.2 activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitors. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies, and/or inhibitors as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.

Abstract: The present invention relates to diagnostic assays whereby the detection means is based on electrochemical reactions. This means that the label to be detected provides an electric signal. Preferred labels are enzymes giving such a signal. Provided is a flow cell whereby a solid phase is provided in a flow stream of the sample, in close proximity to a working electrode to detect any electrical signal. In a typical embodiment, a sample is mixed with molecule having specific binding affinity for an analyte of which the presence in the sample is to be detected, whereby said specific binding molecule is provided with a label. The conjugate of labelled specific binding molecule and analyte is then immobilized on the solid phase in the vicinity of the working electrode, the flow cell is rinsed with a solution and afterwards a substrate solution for the label (an enzyme) is provided upon which an electrical signal is generated and can be detected by the working electrode.

Abstract: The object of the present invention is the oral administration of animal immunoglobulins for the treatment of gastrointestinal disorders caused by bacterial and/or yeast overgrowth. Immunoglobulins derived from the blood, plasma or serum of animals, such as cow, goats, sheep and pigs, contain a broad spectrum of antibodies to bacteria and yeast that afflict the gastrointestinal tract of human patients.

Abstract: The present invention provides fusion protein comprising I.kappa.B and green fluorescent protein. Also provided is DNA encoding this protein and vector expressing such DNA and various methods of using a fusion protein comprising I.kappa.B and green fluorescent protein.

Abstract: Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the patient is administered mitogenically stimulated lymph node lymphocytes or the supernatant therefrom. The lymph node lymphocytes are patient excised lymph node lymphocytes enriched in tumor reactive cells, such as CD4+ tumor reactive cells. Radiolabeled locators (e.g., antibodies) can be used along with a portable radiation detector to intraoperatively determine which lymph nodes bear lymph node lymphocytes enriched in tumor reactive cells. The patient excised lymph node lymphocytes enriched in tumor reactive cells then are subjected to mitogenic stimulation for their expansion and administration to the patient.

Abstract: The present invention provides a composition comprising a BPI Protein and an anionic compound which composition exhibits (1) no bacterial activity and (2) endotoxin neutralizing activity. Also, this invention provides methods for using BPI Proteins.

Abstract: A method of treating cancers by administering to a patient an anti-tumor effective amount ot at least one of a thermostable macromolecular antigen complex or a fragment of such a complex which is interspecific for microorganisms of the Mycobacteria, Nocardia and Corynebacteria group and which exhibits after immunoelectrophoresis an immunoelectrophoretic precipitation pattern corresponding to that of the antigen complex 60 of Mycobacteria bovis Calmette Guerin Bacillus strain. Preferably, the patient is also treated with an additional therapeutic agent which is specific against the patient's cancer such as a tumoral antigen or a non-proliferative tumor cell.

Abstract: The invention is directed to a method and food product for achieving at least one of the following: increasing muscle protein or reducing fat in an animal. The method comprises administering to the animal an effective amount of a composition comprising a gastrointestinal neuro-modulator antibody in order to neutralize the gastrointestinal neuro-modulator.

Abstract: There is disclosed a method of treating ischemia-reperfusion injury comprising administering an effective amount of Interleukin-10 to a patient suffering or expected to suffer from such injury.

Abstract: The present invention relates to new recombinant DNA-molecules comprising nucleotide sequences of S. dygalactiae encoding for at least one protein or polypeptide having fibronectin binding property.

Abstract: This invention relates to a novel infectious bronchitis virus (IBV) serotype and to attenuated IBV strains derived therefrom, and also to live or inactivated vaccines made using such IB virus. This invention also relates to a method for protecting poultry against IBV using these vaccines.

Abstract: Novel response regulator polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides and polypeptides for the treatment of infection, particularly bacterial infections. Antagonists against such the polypeptides of the invention and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence the nucleic acid sequences and the polypeptides of the invention in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding response regulators and for detecting the polypeptide in a host.